Manmohan Biring, MD
Pulmonary Disease · Hays, KSNPI 1770650335
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,725 of the $2,802 with a category attached, or 61.6%. 24 manufacturers reported payments, led by Intuitive Surgical at 30.4% of the total. 2025 is the largest year on record at $1,425, 2.2 times the $641 reported in 2019.
Across 104 payments — averaging $26.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$853
- GSK$303
- Amgen$289
- Inspire Medical Systems, Inc.$190
- Boehringer Ingelheim$175
- Regeneron Healthcare Solutions, Inc.$154
- plus $838 from 18 others
What the payments were for
- Travel & lodging$83630%
- Food & beverage$1,72562%
- Education$2429%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $853 |
| GSK | 21 | $303 |
| Amgen | 13 | $289 |
| Inspire Medical Systems, Inc. | 3 | $190 |
| Boehringer Ingelheim | 8 | $175 |
| Regeneron Healthcare Solutions, Inc. | 4 | $154 |
| Sunovion Pharmaceuticals Inc. | 11 | $149 |
| Genentech USA, Inc. | 7 | $122 |
| AstraZeneca | 6 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| AbbVie | 4 | $52 |
| Pfizer | 4 | $50 |
| Novartis | 3 | $49 |
| United Therapeutics Corporation | 1 | $43 |
| Veran Medical Technologies, Inc. | 2 | $35 |
| Mylan Specialty L.p. | 2 | $34 |
| BD | 1 | $28 |
| Viatris Specialty LLC | 1 | $23 |
| Verona Pharma, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Insmed, Inc. | 1 | $15 |
| CSL Behring | 1 | $13 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$660
- Inspire$102
How this compares
$2,802 in reported general payments places this provider in the 55th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 43 | $443,922 |
| Spiriva RespimatTiotropium Bromide | 279 | $158,299 |
| Incruse ElliptaUmeclidinium Bromide | 147 | $55,082 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $40,360 |
| Breo ElliptaFluticasone/Vilanterol | 88 | $38,353 |
| Advair HfaFluticasone Propion/Salmeterol | 87 | $31,797 |
| SymbicortBudesonide/Formoterol Fumarate | 83 | $23,664 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $21,299 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $14,118 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 94 | $13,495 |
| BreynaBudesonide/Formoterol Fumarate | 62 | $11,338 |
| Fluticasone Propionate HfaFluticasone Propionate | 33 | $10,537 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 21 | $9,080 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $8,970 |
| Pulmicort FlexhalerBudesonide | 31 | $7,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $175 | $616,340351 claims |
| GSKIncruse Ellipta, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta | $303 | $142,766305 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere, Pulmicort Flexhaler | $102 | $61,225167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Hays
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Abdel-Ghanie Abu-SamraWichita$60K
- Robert SourkHutchinson$33K
- Andreas SchmidKansas City$26K
- Harold BarkmanKansas City$24K
- Brandon BowersShawnee Mission$22K
- Heath LathamKansas City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.